Hans Bishop

Mr. Bishop has more than 30 years of experience in the biotech industry and is the CEO of GRAIL, a healthcare company working on early detection of cancer. In 2013, he founded the oncology immunotherapy company Juno Therapeutics and, as CEO, led Juno through the initiation of multiple clinical trials and rapid organizational growth, which attracted its $11 billion acquisition by Celgene just five years later. Previously, he served as an Executive in Residence at Warburg Pincus and held executive positions at Dendreon, Inc., Bayer Healthcare, and Chiron Corporation. He holds a BA in chemistry from Brunel University in London.